A review of rodent models of type 2 diabetic skeletal fragility

Journal of Bone and Mineral Research

Volumn 29, Issue 5, 2014, Pages 1025-1040

  Fajardo, Roberto J ^a   Karim, Lamya ^b   Calley, Virginia I ^a   Bouxsein, Mary L ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

animal models; bone; diabetes; fracture risk; type 2 diabetes

Indexed keywords

BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE MATURATION; BONE METABOLISM; BONE STRENGTH; DISEASE ASSOCIATION; FRACTURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOPOROSIS; REVIEW; RODENT MODEL; ANIMAL; BONE DISEASE; DIABETES MELLITUS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; MOUSE; PATHOLOGY; RAT;

ANIMALS; BONE DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; HUMANS; MICE; RATS;

EID: 84899055916     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2210     Document Type: Review

References (200)

1. Janghorbani M, Van Dam RM, Willett WC, Hu FB,. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166 (5): 495-505.
2. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006; 91 (9): 3404-10.
3. Vestergaard P, Rejnmark L, Mosekilde L,. Has mortality after a hip fracture increased ? J Am Geriatr Soc. 2007; 55 (11): 1720-6.
4. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T,. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009; 24 (4): 702-9.
5. Kilpadi KL, Eldabaje R, Schmitz JE, et al. Type 2 diabetes is associated with vertebral fractures in a sample of clinic- and hospital-based Latinos. J Immigr Minor Health. Forthcoming. Epub 2013 May 1. DOI: 10.1007/s10903-013-9833- 5.
6. Di Somma C, Rubino M, Faggiano A, et al. Spinal deformity index in patients with type 2 diabetes. Endocrine. 2013; 43 (3): 651-8.
7. Viegas M, Costa C, Lopes A, Griz L, Medeiro MA, Bandeira F,. Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J Diabetes Complications. 2011; 25 (4): 216-21.
8. Hernandez RK, Do TP, Critchlow CW, Dent RE, Jick SS,. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthop. 2012; 83 (6): 653-60.
9. Semel J, Gray JM, Ahn HJ, Nasr H, Chen JJ,. Predictors of outcome following hip fracture rehabilitation. Pm r. 2010; 2 (9): 799-805.
10. Reistetter TA, Graham JE, Deutsch A, Markello SJ, Granger CV, Ottenbacher KJ,. Diabetes comorbidity and age influence rehabilitation outcomes after hip fracture. Diabetes Care. 2011; 34 (6): 1375-7.
11. Norris R, Parker M,. Diabetes mellitus and hip fracture: a study of 5966 cases. Injury. 2011; 42 (11): 1313-6.
12. Huang YF, Shyu YI, Liang J, Chen MC, Cheng HS, Wu CC,. Diabetes and health outcomes among older Taiwanese with hip fracture. Rejuvenation Res. 2012; 15 (5): 476-82.
13. Ekström W, Al-Ani AN, Sääf M, Cederholm T, Ponzer S, Hedström M,. Health related quality of life, reoperation rate and function in patients with diabetes mellitus and hip fracture-a 2 year follow-up study. Injury. 2013; 44 (6): 769-75.
14. Bass E, French DD, Bradham DD,. A national perspective of Medicare expenditures for elderly veterans with hip fractures. J Am Med Dir Assoc. 2008; 9 (2): 114-9.
15. National Diabetes Fact Sheet. 2011; [Internet]. Atlanta, GA: Centers for Disease Control and Prevention (US); 2011 [cited 2014 Mar 21]. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf.
16. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87 (3): 293-301.
17. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001; 24 (11): 1936-40.
18. Center for Disease Control and Prevention (CDC). Prevalence of diabetes among Hispanics-selected areas, 1998-2002. MMWR Morb Mortal Wkly Rep. 2004; 53: 941-4.
19. Ottenbacher KJ, Ostir GV, Peek MK, Goodwin JS, Markides KS,. Diabetes mellitus as a risk factor for hip fracture in Mexican American older adults. J Gerontol A Biol Sci Med Sci. 2002; 57 (10): M648-53.
20. Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011; 305 (21): 2184-92.
21. Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012; 27 (2): 301-8.
22. Cefalu WT,. Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition. ILAR J. 2006; 47 (3): 186-98.
23. Clee SM, Attie AD,. The genetic landscape of type 2 diabetes in mice. Endocr Rev. 2007; 28 (1): 48-83.
24. King AJ,. The use of animal models in diabetes research. Br J Pharmacol. 2012; 166 (3): 877-94.
25. Wang YW, Sun GD, Sun J, et al. Spontaneous type 2 diabetic rodent models. J Diabetes Res. 2013; 2013: 401723.
26. Mohamadi A, Cooke DW,. Type 2 diabetes mellitus in children and adolescents. Adolesc Med State Art Rev. 2010 Apr; 21 (1): 103-19.
27. Wilmot EG, Davies MJ, Yates T, Benhalima K, Lawrence IG, Khunti K,. Type 2 diabetes in younger adults: the emerging UK epidemic. Postgrad Med J. 2010; 86 (1022): 711-8.
28. D'Adamo E, Caprio S,. Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care. 2011; 34(Suppl 2): S161-5.
29. Ma L, Oei L, Jiang L, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012; 27 (5): 319-32.
30. Gerdhem P, Isaksson A, Akesson K, Obrant KJ,. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 2005; 16 (12): 1506-12.
31. Dobnig H, Piswanger-Solkner JC, Roth M, et al. J Clin Endocrinol Metab. 2006; 91 (9): 3355-63.
32. Kanazawa I, Yamaguchi T, Yamauchi M, Sugimoto T,. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia. Intern Med. 2009; 48 (21): 1869-73.
33. Achemlal L, Tellal S, Rkiouak F, et al. Bone metabolism in male patients with type 2 diabetes. Clin Rheumatol. 2005; 24 (5): 493-6.
34. Manavalan JS, Cremers S, Dempster DW, et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97 (9): 3240-50.
35. Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int. 2012; 23 (2): 635-41.
36. Iglesias P, Arrieta F, Pinera M, et al. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol (Oxf). 2011; 75 (2): 184-8.
37. Ardawi MS, Akhbar DH, Alshaikh A, et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013; 56 (2): 355-62.
38. Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97 (1): 234-41.
39. Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97 (10): 3744-50.
40. Reyes-Garcia R, Rozas-Moreno P, Lopez-Gallardo G, et al. Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol. 2013; 50 (1): 47-52.
41. Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2012; 97 (5): 1737-44.
42. van Lierop AH, Hamdy NA, van der Meer RW, et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol. 2012; 166 (4): 711-6.
43. Yamamoto M, Yamauchi M, Sugimoto T,. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013; 98 (10): 4030-7.
44. Melton LJ 3rd, Riggs BL, Leibson CL, et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab. 2008; 93 (12): 4804-9.
45. Petit MA, Paudel ML, Taylor BC, et al. Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J Bone Miner Res. 2010; 25 (2): 285-91.
46. Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010; 95 (11): 5045-55.
47. Pritchard JM, Giangregorio LM, Atkinson SA, et al. Association of larger holes in the trabecular bone at the distal radius in postmenopausal women with type 2 diabetes mellitus compared to controls. Arthritis Care Res (Hoboken). 2012; 64 (1): 83-91.
48. Patsch JM, Li X, Baum T, et al. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res. 2013 Aug; 28 (8): 1721-8.
49. Leslie WD, Rubin MR, Schwartz AV, Kanis JA,. Type 2 diabetes and bone. J Bone Miner Res. 2012; 27 (11): 2231-7.
50. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T,. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93 (3): 1013-9.
51. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94 (7): 2380-6.
52. Farr JN, Drake MT, Amin S, Melton LJ 3rd., McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014; 29 (4): 787-95.
53. Srinivasan K, Ramarao P,. Animal models in type 2 diabetes research: an overview. Indian J Med Res. 2007; 125 (3): 451-72.
54. Li D, Inouye J, Davis J, Arakaki RF,. Associations between psychosocial and physiological factors and diabetes health indicators in Asian and Pacific Islander adults with type 2 diabetes. Nurs Res Pract. 2013; 2013: 703520.
55. Glatt V, Canalis E, Stadmeyer L, Bouxsein ML,. Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res. 2007; 22 (8): 1197-207.
56. Hughes PC, Tanner JM,. The assessment of skeletal maturity in the growing rat. J Anat. 1970; 106 (Pt 2): 371-402.
57. Beamer WG, Donahue LR, Rosen CJ, Baylink DJ,. Genetic variability in adult bone density among inbred strains of mice. Bone. 1996; 18 (5): 397-403.
58. Buie HR, Moore CP, Boyd SK,. Postpubertal architectural developmental patterns differ between the L3 vertebra and proximal tibia in three inbred strains of mice. J Bone Miner Res. 2008; 23 (12): 2048-59.
59. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T,. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992; 41 (11): 1422-8.
60. Shinohara M, Masuyama T, Shoda T, et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res. 2000; 1 (2): 89-100.
61. Reinwald S, Peterson RG, Allen MR, Burr DB,. Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models. Am J Physiol Endocrinol Metab. 2009; 296 (4): E765-74.
62. Masuyama T, Komeda K, Hara A, et al. Chronological characterization of diabetes development in male Spontaneously Diabetic Torii rats. Biochem Biophys Res Commun. 2004; 314 (3): 870-7.
63. Svenson KL, Von Smith R, Magnani PA, et al. Multiple trait measurements in 43 inbred mouse strains capture the phenotypic diversity characteristic of human populations. J Appl Physiol. 2007; 102 (6): 2369-78.
64. Hoshi S, Shu Y, Yoshida F, et al. Podocyte injury promotes progressive nephropathy in Zucker Diabetic Fatty rats. Lab Invest. 2002; 82 (1): 25-35.
65. Scherzer P, Katalan S, Got G, et al. Psammomys obesus, a particularly important animal model for the study of the human diabetic nephropathy. Anat Cell Biol. 2011; 44 (3): 176-85.
66. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN,. Diet-induced type II diabetes in C57BL/6J mice. Diabetes. 1988; 37 (9): 1163-7.
67. Inzana JA, Kung M, Shu L, et al. Immature mice are more susceptible to the detrimental effects of high fat diet on cancellous bone in the distal femur. Bone. 2013; 57 (1): 174-83.
68. Ionova-Martin SS, Do SH, Barth HD, et al. Reduced size-independent mechanical properties of cortical bone in high-fat diet-induced obesity. Bone. 2010; 46 (1): 217-25.
69. Rossmeisl M, Rim JS, Koza RA, Kozak LP,. Variation in type 2 diabetes-related traits in mouse strains susceptible to diet-induced obesity. Diabetes. 2003; 52 (8): 1958-66.
70. Ables GP, Perrone CE, Orentreich D, Orentreich N,. Methionine-restricted C57BL/6J mice are resistant to diet-induced obesity and insulin resistance but have low bone density. PLoS One. 2012; 7 (12): e51357.
71. Ahren B, Pacini G,. Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice. Am J Physiol Endocrinol Metab. 2002; 283 (4): E738-44.
72. Ionova-Martin SS, Wade JM, Tang S, et al. Changes in cortical bone response to high-fat diet from adolescence to adulthood in mice. Osteoporos Int. 2011; 22 (8): 2283-93.
73. Goren HJ, Kulkarni RN, Kahn CR,. Glucose homeostasis and tissue transcript content of insulin signaling 129 × 1. Endocrinology. 2004; 145 (7): 3307-23.
74. Deji N, Kume S, Araki S, et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol. 2009; 296 (1): F118-26.
75. Obrosova IG, Ilnytska O, Lyzogubov VV, et al. High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes. 2007; 56 (10): 2598-608.
76. Cao JJ, Gregoire BR, Gao H,. High-fat diet decreases cancellous bone mass but has no effect on cortical bone mass in the tibia in mice. Bone. 2009; 44 (6): 1097-104.
77. Halade GV, Rahman MM, Williams PJ, Fernandes G,. High fat diet-induced animal model of age-associated obesity and osteoporosis. J Nutr Biochem. 2010; 21 (12): 1162-9.
78. Patsch JM, Kiefer FW, Varga P, et al. Increased bone resorption and impaired bone microarchitecture in short-term and extended high-fat diet-induced obesity. Metabolism. 2011; 60 (2): 243-9.
79. Baek K, Hwang HR, Park H, et al. TNF-alpha upregulates sclerostin expression in obese mice fed a high-fat diet. J Cell Physiol. 2014 May; 229 (5): 640-50.
80. Fujita Y, Watanabe K, Maki K,. Serum leptin levels negatively correlate with trabecular bone mineral density in high-fat diet-induced obesity mice. J Musculoskelet Neuronal Interact. 2012; 12 (2): 84-94.
81. Fernandez AM, Kim JK, Yakar S, et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 2001; 15 (15): 1926-34.
82. Kawashima Y, Fritton JC, Yakar S, et al. Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone. 2009; 44 (4): 648-55.
83. Vaitheesvaran B, LeRoith D, Kurland IJ,. MKR mice have increased dynamic glucose disposal despite metabolic inflexibility, and hepatic and peripheral insulin insensitivity. Diabetologia. 2010; 53 (10): 2224-32.
84. Li X, Wu X, Camacho R, Schwartz GJ, LeRoith D,. Intracerebroventricular leptin infusion improves glucose homeostasis in lean type 2 diabetic MKR mice via hepatic vagal and non-vagal mechanisms. PLoS One. 2011; 6 (2): e17058.
85. Kim JH, Stewart TP, Soltani-Bejnood M, et al. Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. J Endocrinol. 2006; 191 (2): 437-6.
86. Castracane VD, Henson MC,. The obese (ob/ob) mouse and the discovery of leptin. In:, Castracane VD, Henson MC, editors. Leptin. New York: Springer; 2007. p. 1-9. (Endocrine updates: vol. 25).
87. Lindström P,. The physiology of obese-hyperglycemic mice [ob/ob mice]. ScientificWorldJournal. 2007; 7: 666-85.
88. Chehab FF, Lim ME,. Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet. 1996; 12 (3): 318-20.
89. Heep H, Wedemeyer C, Wegner A, Hofmeister S, von Knoch M,. Differences in trabecular bone of leptin-deficient ob/ob mice in response to biomechanical loading. Int J Biol Sci. 2008; 4 (3): 169-75.
90. Kondo T, Kahn CR,. Altered insulin signaling in retinal tissue in diabetic states. J Biol Chem. 2004; 279 (36): 37997-8006.
91. Drel VR, Mashtalir N, Ilnytska O, et al. The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity. Diabetes. 2006; 55 (12): 3335-43.
92. Coleman DL,. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia. 1978; 14 (3): 141-8.
93. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000; 100 (2): 197-207.
94. Ealey KN, Fonseca D, Archer MC, Ward WE,. Bone abnormalities in adolescent leptin-deficient mice. Regul Pept. 2006; 136 (1-3): 9-13.
95. Matsunuma A, Kawane T, Maeda T, Hamada S, Horiuchi N,. Leptin corrects increased gene expression of renal 25-hydroxyvitamin D 3-1 alpha-hydroxylase and -24-hydroxylase in leptin-deficient, ob/ob mice. Endocrinology. 2004; 145 (3): 1367-75.
96. Hamrick MW, Pennington C, Newton D, Xie D, Isales C,. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone. 2004; 34 (3): 376-83.
97. Turner RT, Kalra SP, Wong CP, et al. Peripheral leptin regulates bone formation. J Bone Miner Res. 2013; 28 (1): 22-34.
98. Shafrir E,. Diabetes in animals: contribution to the understanding of diabetes by study of its etiopathology in animal models. In:, Porte D, Sherwin R, Baron A, editors. Diabetes mellitus. New York: McGraw-Hill; p. 231-55. 2003.
99. Orland MJ, Permutt MA,. Quantitative analysis of pancreatic proinsulin mRNA in genetically diabetic (db/db) mice. Diabetes. 1987; 36 (3): 341-7.
100. Gao Q, Wolfgang MJ, Neschen S, et al. Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci U S A. 2004; 101 (13): 4661-6.
101. Like AA, Lavine RL, Poffenbarger PL, Chick WL,. Studies in the diabetic mutant mouse. VI. Evolution of glomerular lesions and associated proteinuria. Am J Pathol. 1972; 66 (2): 193-224.
102. Xiao C, He M, Nan Y, et al. Physiological effects of superoxide dismutase on altered visual function of retinal ganglion cells in db/db mice. PLoS One. 2012; 7 (1): e30343.
103. Aasum E, Hafstad AD, Severson DL, Larsen TS,. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes. 2003; 52 (2): 434-1.
104. Hosokawa T,. [Altered bone metabolism in db/db mice]. Nihon Ronen Igakkai Zasshi. 1992; 29 (7-8): 540-8.
105. Lorentzon R, Alehagen U, Boquist L,. Osteopenia in mice with genetic diabetes. Diabetes Res Clin Pract. 1986; 2 (3): 157-63.
106. Takeshita N, Mutoh S, Yamaguchi I,. Osteopenia in genetically diabetic DB/DB mice and effects of 1alpha-hydroxyvitamin D3 on the osteopenia. Basic Research Group. Life Sci. 1995; 56 (13): 1095-101.
107. Williams GA, Callon KE, Watson M, et al. Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res. 2011; 26 (8): 1698-709.
108. Tomino Y,. Lessons from the KK-Ay mouse, a spontaneous animal model for the treatment of human type 2 diabetic nephropathy. Nephrourol Mon. 2012; 4 (3): 524-9.
109. Okazaki M, Saito Y, Udaka Y, et al. Diabetic nephropathy in KK and KK-Ay mice. Exp Anim. 2002; 51 (2): 191-6.
110. Takagi S, Miura T, Yamashita T, et al. Characteristics of diabetic osteopenia in KK-Ay diabetic mice. Biol Pharm Bull. 2012; 35 (3): 438-43.
111. Kim JH, Stewart TP, Zhang W, Kim HY, Nishina PM, Naggert JK,. Type 2 diabetes mouse model TallyHo carries an obesity gene on chromosome 6 that exaggerates dietary obesity. Physiol Genomics. 2005; 22 (2): 171-81.
112. Kim JH, Sen S, Avery CS, et al. Genetic analysis of a new mouse model for non-insulin-dependent diabetes. Genomics. 2001; 74 (3): 273-86.
113. Won HY, Lee JA, Park ZS, et al. Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T cells in TallyHo/JngJ mice. PLoS One. 2011; 6 (3): e18168.
114. Kim JH, Saxton AM,. The TALLYHO mouse as a model of human type 2 diabetes. Methods Mol Biol. 2012; 933: 75-87.
115. Nakamura N,. Reduced aldehyde dehydrogenase activity and arginine vasopressin receptor 2 expression in the kidneys of male TALLYHO/JngJ mice of prediabetic age. Endocrine. 2011; 40 (3): 379-85.
116. Buck DW 2nd, Jin daP, Geringer M, Hong SJ, Galiano RD, Mustoe TA,. The TallyHo polygenic mouse model of diabetes: implications in wound healing. Plast Reconstr Surg. 2011; 128 (5): 427e-37e.
117. Devlin M, Van Vliet M, Conlon C, Louis L, Karim L, Bouxsein ML,. Early onset type 2 diabetes impairs skeletal acquisition in the Tallyho mouse. J Bone Miner Res. 2012; 27 Suppl 1. [Poster session presented at: Annual Meeting American Society for Bone and Mineral Research (ASBMR); 2012 Oct 12-15; Minneapolis, MN, USA; Presentation Number: SA0029]. Available from: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= 9941931e-7870-4e35-830e-d8dcd4c68ce0.
118. Allan MF, Eisen EJ, Pomp D,. The M16 mouse: an outbred animal model of early onset polygenic obesity and diabesity. Obes Res. 2004; 12 (9): 1397-407.
119. Eisen EJ, Leatherwood JM,. Adipose cellularity and body composition in polygenic obese mice as influenced by preweaning nutrition. J Nutr. 1978; 108 (10): 1652-62.
120. Ueda H, Ikegami H, Yamato E, et al. The NSY mouse: a new animal model of spontaneous NIDDM with moderate obesity. Diabetologia. 1995; 38 (5): 503-8.
121. Shibata M, Kawanishi A, Kishi T, et al. Inhibitory effect of elastase on the glomerular capillary basement membrane thickening of the experimental congenital diabetic mice (N.S.Y. mice). Nagoya J Med Sci. 1981; 43 (3-4): 111-5.
122. Shibata M,. Microangiopathy in diabetic N.S.Y. mice. In:, Abe H, Hoshi M, editors. Diabetic macroangiopathy. Tokyo: University of Tokyo Press; p. 457-66. 1983.
123. Shimizu K, Morita H, Niwa T, et al. Spontaneous amyloidosis in senile NSY mice. Acta Pathol Jpn. 1993; 43 (5): 215-21.
124. Suzuki W, Iizuka S, Tabuchi M, et al. A new mouse model of spontaneous diabetes derived from ddY strain. Exp Anim. 1999; 48 (3): 181-9.
125. Hirayama I, Yi Z, Izumi S, et al. Genetic analysis of obese diabetes in the TSOD mouse. Diabetes. 1999; 48 (5): 1183-91.
126. Iizuka S, Suzuki W, Tabuchi M, et al. Diabetic complications in a new animal model (TSOD mouse) of spontaneous NIDDM with obesity. Exp Anim. 2005; 54 (1): 71-83.
127. Miura T, Suzuki W, Ishihara E, et al. Impairment of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue in the Tsumura Suzuki obese diabetic mouse: a new genetic animal model of type 2 diabetes. Eur J Endocrinol. 2001; 145 (6): 785-90.
128. Breyer MD, Böttinger E, Brosius FC, et al. Animal Models of Diabetic Complications Consortium (AMDCC). Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005; 16 (1): 27-45.
129. Igel M, Taylor BA, Phillips SJ, Becker W, Herberg L, Joost HG,. Hyperleptinemia and leptin receptor variant Asp600Asn in the obese, hyperinsulinemic KK mouse strain. J Mol Endocrinol. 1998; 21 (3): 337-45.
130. Ikeda H, mouse KK,. Diabetes Res Clin Pract. 1994;(24 Suppl): S313-6.
131. Duhalt J, Lebon F, Boulanger M,. KK mice as a model of microangiopathic lesions in diabetes. Seventh European Conference on Microcirculation. Aberdeen: Karger; 1973; p. 453-8.
132. Koza RA, Flurkey K, Graunke DM, et al. Contributions of dysregulated energy metabolism to type 2 diabetes development in NZO/H1Lt mice with polygenic obesity. Metabolism. 2004; 53 (6): 799-808.
133. Reifsnyder PC, Leiter EH,. Deconstructing and reconstructing obesity-induced diabetes (diabesity) in mice. Diabetes. 2002; 51 (3): 825-32.
134. Subrahmanyam K,. Metabolism in the New Zealand strain of obese mice. Biochem J. 1960; 76 (3): 548-56.
135. Thorburn AW, Holdsworth A, Proietto J, Morahan G,. Differential and genetically separable associations of leptin with obesity-related traits. Int J Obes Relat Metab Disord. 2000; 24 (6): 742-50.
136. Melez KA, Harrison LC, Gilliam JN, Steinberg AD,. Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse. Diabetes. 1980; 29 (10): 835-40.
137. Leiter EH, Reifsnyder PC,. Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes. 2004; 53 (Suppl 1): S4-11.
138. Bielschowsky M, Bielschowsky F,. Observations on Nzb/B1 mice; differential fertility in reciprocal crosses and the transmission of the auto-immune haemolytic anaemia to Nzb/B1 X Nzc/B1 hybrids. Aust J Exp Biol Med Sci. 1964; 42: 561-8.
139. Kaiser N, Nesher R, Donath MY, et al. Diabetes. 2005; 54 (Suppl 2): S137-44.
140. Wuarin-Bierman L, Zahnd GR, Kaufmann F, Burcklen L, Adler J,. Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy. Diabetologia. 1987; 30 (8): 653-8.
141. Walder KR, Fahey RP, Morton GJ, Zimmet PZ, Collier GR,. Characterization of obesity phenotypes in Psammomys obesus (Israeli sand rats). Int J Exp Diabetes Res. 2000; 1 (3): 177-84.
142. Shafrir E, Ziv E, Kalman R,. Nutritionally induced diabetes in desert rodents as models of type 2 diabetes: Acomys cahirinus (spiny mice) and Psammomys obesus (desert gerbil). ILAR J. 2006; 47 (3): 212-24.
143. Neel JV,. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress "? Am J Hum Genet. 1962; 14: 353-62.
144. Amir G, Adler JH, Menczel J,. Histomorphometric analysis of weight bearing bones of diabetic and non-diabetic sand rats (Psammomys obesus). Diabetes Res. 1991; 17 (3): 135-7.
145. Silberberg R,. Morphometric analysis of cancellous bone of young diabetic and non-diabetic sand rats (Psammomys obesus). Diabetes Res. 1987; 5 (3): 149-51.
146. Peterson RG, Shaw WN, Neel A-A, Little LA, Eichberg J,. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR J. 1990; 32 (3): 16-9.
147. Brussee V, Guo G, Dong Y, et al. Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model. Diabetes. 2008; 57 (6): 1664-73.
148. Gassler N, Elger M, Kranzlin B, et al. Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat. Kidney Int. 2001; 60 (1): 106-16.
149. Mathey J, Horcajada-Molteni MN, Chanteranne B, et al. Bone mass in obese diabetic Zucker rats: influence of treadmill running. Calcif Tissue Int. 2002; 70 (4): 305-11.
150. Prisby RD, Swift JM, Bloomfield SA, Hogan HA, Delp MD,. Altered bone mass, geometry and mechanical properties during the development and progression of type 2 diabetes in the Zucker diabetic fatty rat. J Endocrinol. 2008; 199 (3): 379-88.
151. Hamann C, Rauner M, Hohna Y, et al. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res. 2013; 28 (3): 627-38.
152. Hamann C, Goettsch C, Mettelsiefen J, et al. Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am J Physiol Endocrinol Metab. 2011; 301 (6): E1220-8.
153. Liu Z, Aronson J, Wahl EC, et al. A novel rat model for the study of deficits in bone formation in type-2 diabetes. Acta Orthop. 2007; 78 (1): 46-55.
154. Abdel-Halim SM, Guenifi A, Luthman H, Grill V, Efendic S, Ostenson CG,. Impact of diabetic inheritance on glucose tolerance and insulin secretion in spontaneously diabetic GK-Wistar rats. Diabetes. 1994; 43 (2): 281-8.
155. Picarel-Blanchot F, Berthelier C, Bailbe D, Portha B,. Impaired insulin secretion and excessive hepatic glucose production are both early events in the diabetic GK rat. Am J Physiol. 1996; 271 (4 Pt 1): E755-62.
156. Bisbis S, Bailbe D, Tormo MA, et al. Insulin resistance in the GK rat: decreased receptor number but normal kinase activity in liver. Am J Physiol. 1993; 265 (5 Pt 1): E807-13.
157. Cao Y, Dubois DC, Sun H, Almon RR, Jusko WJ,. Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats. J Pharmacol Exp Ther. 2011; 339 (3): 896-04.
158. Ostenson CG,. The Goto-Kakizaki rat. In:, Sima AAF, Shafrir E, editors. Animal models in diabetes: a primer. New York: Harwood Academic Publishers; p. 197-211. (Frontiers in Animal Diabetes Research: vol. 2) 2001.
159. Agardh CD, Agardh E, Zhang H, Ostenson CG,. Altered endothelial/pericyte ratio in Goto-Kakizaki rat retina. J Diabetes Complications. 1997; 11 (3): 158-62.
160. Janssen U, Riley SG, Vassiliadou A, Floege J, Phillips AO,. Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. Kidney Int. 2003; 63 (6): 2162-70.
161. Janssen U, Vassiliadou A, Riley SG, Phillips AO, Floege J,. The quest for a model of type II diabetes with nephropathy: the Goto Kakizaki rat. J Nephrol. 2004; 17 (6): 769-73.
162. Wada R, Koyama M, Mizukami H, Odaka H, Ikeda H, Yagihashi S,. Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: a genetic model for type 2 diabetes. Diabetes Metab Res Rev. 1999; 15 (5): 332-7.
163. Ueta K, Ishihara T, Matsumoto Y, et al. Long-term treatment with the Na + -glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci. 2005; 76 (23): 2655-68.
164. Ahmad T, Ohlsson C, Saaf M, Ostenson CG, Kreicbergs A,. Skeletal changes in type-2 diabetic Goto-Kakizaki rats. J Endocrinol. 2003; 178 (1): 111-6.
165. Zhang L, Liu Y, Wang D, et al. Bone biomechanical and histomorphometrical investment in type 2 diabetic Goto-Kakizaki rats. Acta Diabetol. 2009; 46: 119-26.
166. Miao G, Ito T, Uchikoshi F, et al. Stage-dependent effect of pancreatic transplantation on diabetic ocular complications in the Spontaneously Diabetic Torii rat. Transplantation. 2004; 77 (5): 658-63.
167. Miao G, Ito T, Uchikoshi F, et al. Beneficial effects of pancreas transplantation: regeneration of pancreatic islets in the spontaneously diabetic Torii rat. Transplant Proc. 2005; 37 (1): 226-8.
168. Kakehashi A, Saito Y, Mori K, et al. Characteristics of diabetic retinopathy in SDT rats. Diabetes Metab Res Rev. 2006; 22 (6): 455-61.
169. Sasase T, Ohta T, Masuyama T, Yokoi N, Kakehashi A, Shinohara M,. The spontaneously diabetic torii rat: an animal model of nonobese type 2 diabetes with severe diabetic complications. J Diabetes Res. 2013; 2013: 976209.
170. Ohta T, Matsui K, Miyajima K, et al. Effect of insulin therapy on renal changes in spontaneously diabetic Torii rats. Exp Anim. 2007; 56 (5): 355-62.
171. Fujii H, Hamada Y, Fukagawa M,. Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats. Bone. 2008; 42 (2): 372-9.
172. Goto S, Fujii H, Kono K, et al. Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes. Am J Nephrol. 2011; 34 (3): 281-90.
173. Davis JE, Cain J, Banz WJ, Peterson RG,. Age-related differences in response to high-fat feeding on adipose tissue and metabolic profile in ZDSD rats. ISRN Obes. 2013 May 20; 2013; 584547. DOI: 10.1155/2013/584547.
174. Gonzalez AD, Gallant MA, Burr DB, Wallace JM,. Multiscale analysis of morphology and mechanics in tail tendon from the ZDSD rat model of type 2 diabetes. J Biomech. 2014; 47 (3): 681-6.
175. Gattone V, Peterson RG, Zimmerman K,. Diabetic nephropathy in the ZDSD rat. Nephrol Dial Transplant. 2012; 27 (Suppl 2): ii159-66. DOI: 10.1093/ndt/gfs220. [Presented at: 49th ERA-EDTA Congress; 2012 May 24-27; Paris, France;; Presentation Number: FP260].
176. Gallant MA, Brown DM, Organ JM, Allen MR, Burr DB,. Reference-point indentation correlates with bone toughness assessed using whole-bone traditional mechanical testing. Bone. 2013; 53 (1): 301-5.
177. Choi KC, Ryu OH, Lee KW, et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun. 2005; 336 (3): 747-53.
178. Won HY, Park JB, Park EY, Riew KD,. Effect of hyperglycemia on apoptosis of notochordal cells and intervertebral disc degeneration in diabetic rats. J Neurosurg Spine. 2009; 11 (6): 741-8.
179. Kim JY, Lee SK, Jo KJ, et al. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of
180. Fukaya N, Mochizuki K, Shimada M, Goda T,. The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes. Nutrition. 2009; 25 (6): 657-67.
181. Lee HJ, Choi SS, Park MK, et al. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun. 2002; 296 (2): 293-9.
182. Yang SJ, Choi JM, Kim L, et al. Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes. J Nutr Biochem. 2014; 25 (1): 66-72.
183. Fukuzawa Y, Watanabe Y, Inaguma D, Hotta N,. Evaluation of glomerular lesion and abnormal urinary findings in OLETF rats resulting from a long-term diabetic state. J Lab Clin Med. 1996; 128 (6): 568-78.
184. Nakamura J, Hamada Y, Sakakibara F, et al. Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats. Diabetes Res Clin Pract. 2001; 51 (1): 9-20.
185. Nakamura J, Koh N, Sakakibara F, et al. Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats: effect of an aldose reductase inhibitor. TAT. Life Sci. 1997; 60 (21): 1847-57.
186. Kamenov Z, Higashino H, Todorova M, Kajimoto N, Suzuki A,. Physiological characteristics of diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats. Methods Find Exp Clin Pharmacol. 2006; 28 (1): 13-8.
187. Lu ZY, Bhutto IA, Amemiya T,. Retinal changes in Otsuka Long-Evans Tokushima Fatty rats (spontaneously diabetic rat)-possibility of a new experimental model for diabetic retinopathy. Jpn J Ophthalmol. 2003; 47 (1): 28-35.
188. Matsuura T, Yamagishi S, Kodama Y, Shibata R, Ueda S, Narama I,. Otsuka Long-Evans Tokushima fatty (OLETF) rat is not a suitable animal model for the study of angiopathic diabetic retinopathy. Int J Tissue React. 2005; 27 (2): 59-62.
189. Omi N, Maruyama T, Suzuki Y, Ezawa I,. Bone loss in a rat model of non-insulin-dependent diabetes mellitus, the OLETF (Otsuka Long-Evans Tokashima fatty strain) rat. J Bone Miner Metab. 1998; 16: 250-8.
190. El-Aoufi S, Lazourgui MA, Griene L, Maouche B,. Atherosclerosis and atherosensitivity in two southwest Algerian desert rodents, Psammomys obesus and Gerbillus gerbillus, and in Rattus norvegicus. Diabetes Metab Syndr Obes. 2012; 5: 337-45.
191. Barnett M, Collier GR, Collier FM, Zimmet P, O'Dea K,. A cross-sectional and short-term longitudinal characterisation of NIDDM in Psammomys obesus. Diabetologia. 1994; 37 (7): 671-6.
192. Kume S, Kato S, Yamagishi S, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and. J Bone Miner Res. 2005; 20 (9): 1647-58.
193. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P,. Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci. 2008; 1126: 166-72.
194. Pollock NK, Bernard PJ, Wenger K, et al. Lower bone mass in prepubertal overweight children with prediabetes. J Bone Miner Res. 2010; 25 (12): 2760-9.
195. Nagaya T, Yoshida H, Takahashi H, Kawai M,. Increases in body mass index, even within non-obese levels, raise the risk for Type 2 diabetes mellitus: a follow-up study in a Japanese population. Diabet Med. 2005; 22 (8): 1107-11.
196. Shan PF, Wu XP, Zhang H, et al. Bone mineral density and its relationship with body mass index in postmenopausal women with type 2 diabetes mellitus in mainland China. J Bone Miner Metab. 2009; 27 (2): 190-7.
197. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care. 1997; 20 (10): 1562-8.
198. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism. 2004; 53 (7): 831-5.
199. Xu F, Ye YP, Dong YH, Guo FJ, Chen AM, Huang SL,. Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro. J Huazhong Univ Sci Technolog Med Sci. 2013; 33 (2): 244-9.
200. Arakawa K, Ishihara T, Oku A, et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol. 2001; 132 (2): 578-86.